Results of the MARS study on the management of antiangiogenics’ renovascular safety in ovarian cancer.

Launay‐Vacher, Vincent; Janus, Nicolas; Selle, Frédèric; Goldwasser, François; Mir, Olivier; Spano, Jean‐Philippe; Thery, Jean Christophe; Beuzeboc, Philippe; Rey, Jean‐Baptiste; Jouannaud, Christelle; Morère, J. F.; Оудард, С.; Gligorov, Joseph; Azizi, Michel; Dorent, Richard; Deray, Gilbert; Scotté, Florian

doi:10.1200/jco.2013.31.15_suppl.5567

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 That same study found increased plasma concentrations of renin, angiotensin II, and aldosterone in patients. Several studies have found a significant prevalence of proteinuria with VSP inhibitor therapy, ranging from 15–36% in patients treated with bevacizumab 39–41 and TKIs. 42–43 In these studies, the incidence of severe proteinuria (defined as more than 3.5 g in a 24-hour urine collection or 4+ on a urine dipstick) was generally less than 10%.…”

Section: Renal Effects Of Vsp Inhibition Leading To Hypertensionmentioning

confidence: 99%

Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease

et al. 2018

View full text Add to dashboard Cite

Section: Renal Effects Of Vsp Inhibition Leading To Hypertensionmentioning

confidence: 99%

Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease

et al. 2018

View full text Add to dashboard Cite

“…Among them, 249 had mRCC, and 112 of these were treated with sunitinib (12). Other patient groups included patients with breast, lung, ovarian, and colorectal cancer; most of them were treated with bevacizumab (13)(14)(15)(16).…”

Section: Resultsmentioning

confidence: 99%

Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria

Launay‐Vacher

Goldwasser

Mir

et al. 2017

Journal of Onco-Nephrology

Self Cite

View full text Add to dashboard Cite

Background: The potential prognostic value of hypertension and proteinuria of anti-vascular endothelial growth factor (VEGF) drugs has not been assessed in routine clinical practice so far in metastatic renal cell carcinoma (mRCC). The objectives were to (i) assess the prevalence of proteinuria and hypertension at baseline; (ii) their incidence under anti-VEGF drug treatment; and (iii) evaluate a possible link with overall survival. Methods: Patients from 8 centers were included between 2009 and 2011 with a follow-up of 1 year. They were naïve of any previous anti-VEGF drug treatment and planned to be started on one. The results of the group of patients with mRCC receiving sunitinib are presented. Results: A total of 1,124 patients were included, among whom 137 had mRCC and 112 received sunitinib. At inclusion, hypertension prevalence was 44%, proteinuria 16%, hematuria 8%, mean modification of diet in renal disease (MDRD) formula 69 mL/min/1.73m2. The incidence of de novo proteinuria and hypertension during follow-up was 75% and 21%, respectively. Among patients with de novo proteinuria, 76% afterwards improved/normalized. Mean MDRD was 72 at the end of follow-up. No thrombotic microangiopathy was reported. Baseline or de novo proteinuria or hypertension were not associated with OS in mRCC patients treated with sunitinib. Conclusions: These results showed that (i) hypertension and proteinuria were frequent at baseline in mRCC patients; (ii) de novo hypertension and proteinuria frequently occur under sunitinib treatment; and (iii) neither hypertension nor proteinuria, either at baseline or de novo, were associated with overall survival in our cohort of "real-life" patients.

show abstract

“…Anti-VEGF drugs cause dysfunction of the glomerular endothelial cells and disruption of the filtration barrier, leading to proteinuria, hypertension, and -rarely -thrombotic microangiopathy (31,32). The results of the Management of Antiangiogenics Renovascular Safety (MARS) study, a prospective, multicenter study conducted in France to assess the safety of anti-VEGF drugs, showed de novo hypertension in 17.1%, 22.1%, and 12.9% of patients treated with bevacizumab for ovarian, lung, and breast cancers, respectively (33)(34)(35). De novo proteinuria was seen in 36.4%, 72.1%, and 15% of patients treated with bevacizumab for ovarian, lung, and breast cancers, respectively (33)(34)(35).…”

Section: Vegf Inhibitorsmentioning

confidence: 99%

“…The results of the Management of Antiangiogenics Renovascular Safety (MARS) study, a prospective, multicenter study conducted in France to assess the safety of anti-VEGF drugs, showed de novo hypertension in 17.1%, 22.1%, and 12.9% of patients treated with bevacizumab for ovarian, lung, and breast cancers, respectively (33)(34)(35). De novo proteinuria was seen in 36.4%, 72.1%, and 15% of patients treated with bevacizumab for ovarian, lung, and breast cancers, respectively (33)(34)(35). There were no reported cases of thrombotic microangiopathy in the 1,126 patients treated with bevacizumab in the MARS study (33)(34)(35).…”

Section: Vegf Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Chronic Kidney Disease as a Complication of Cancer

Selamet

Abudayyeh

2017

Journal of Onco-Nephrology

View full text Add to dashboard Cite

In recent years, with eligibility for newer drugs and clinical trials highly dependent on kidney function, it has been recognized that CKD is an important aspect of the cancer patient's care. CKD can affect the bioavailability of the cancer treatment, leading to under-dosing, which affects treatment outcome (21). Conversely, the cancer treatment may lead to further renal injury and therefore progressive CKD, limiting further treatment options. With the emergence of targeted therapies and the associated prolonged survival, it has become evident that there is an associated increased risk of renal impairment. This is most evident in patients with renal cell cancer (RCC) who have only one kidney (22, 23). A few large-scale observational studies in Europe have systematically examined the prevalence of CKD among patients with solid tumors. The Renal Insufficiency and Anticancer Medications (IRMA)-1 and-2 are French national observational studies which included about 5,000 cancer patients each (4,684 patients in IRMA-1 and 4,945 in IRMA-2), representing mainly breast, colorectal, lung, ovarian, and prostate cancers (1, 2). About half of the patients in each trial had nonmetastatic disease, and none of them were on dialysis at the time of enrollment. The mean patient ages were 58.1 in IRMA-1 and 59.4 years in IRMA-2. Kidney functions of the patients in these cohorts were assessed with the abbreviated Modification of Diet in Renal Disease formula (aMDRD). The investigators showed that 52.9% of the patients in IRMA-1 and 50.2% of the patients in IRMA-2 had decreased estimated glomerular filtration rate (eGFR) of <90 mL/min/1.73 m 2. CKD stage 3 or higher (eGFR <60 mL/min/1.73 m 2) was observed in 12% of

show abstract

Results of the MARS study on the management of antiangiogenics’ renovascular safety in ovarian cancer.

Cited by 6 publications

References 0 publications

Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease

Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease

Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria

Chronic Kidney Disease as a Complication of Cancer

Contact Info

Product

Resources

About